SLNO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

0.616

-148.52%

0.684

-171.96%

0.935

-1139.39%

Estimates Revision

The market is revising Upward the revenue expectations for Soleno Therapeutics, Inc. (SLNO) for FY2025, with the revenue forecasts being adjusted by 25.96% over the past three months. During the same period, the stock price has changed by -34.41%.

Revenue Estimates for FY2025

Revise Upward

+25.96%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-128.07%

In Past 3 Month

Stock Price

Go Down

-34.41%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast SLNO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLNO is 118.50 USD with a low forecast of 106.00 USD and a high forecast of 145.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

106.00

Averages

118.50

High

145.00

Current: 0.000

Low

106.00

Averages

118.50

High

145.00

Wolfe Research

Kalpit Patel

Outperform

initiated

$75

2025-11-17

Reason

Wolfe Research

Kalpit Patel

Price Target

$75

2025-11-17

initiated

Outperform

Reason

Wolfe Research analyst Kalpit Patel initiated coverage of Soleno Therapeutics with an Outperform rating and $75 price target. Shares have been weak following a slowing of new patient starts quarter-over-quarter, but the firm's survey results suggest that the safety concerns are "overblown" and the directional trend for utilization is favorable for the next one to two years, the analyst tells investors.

Wells Fargo

Derek Archila

Overweight

downgrade

$123 -> $106

2025-11-05

Reason

Wells Fargo

Derek Archila

Price Target

$123 -> $106

2025-11-05

downgrade

Overweight

Reason

Wells Fargo analyst Derek Archila lowered the firm's price target on Soleno Therapeutics to $106 from $123 and keeps an Overweight rating on the shares. The firm says that while this is not the quarter it hoped for exactly, Wells still thinks Vykat XR will be a $1B-plus drug in Prader-Willi syndrome. The firm expects shares to be volatile through year-end 2025 on competitor data but sees the opportunity for shares to outperform on Q4 revenues amid low expectations.

Wells Fargo

Overweight

maintain

$123

2025-09-24

Reason

Wells Fargo

Price Target

$123

2025-09-24

maintain

Overweight

Reason

Wells Fargo believes Acadia Pharmaceuticals' (ACAD) Phase 3 failure removes a near-term competitor to Soleno Therapeutics' (SLNO) VYKAT XR. Wells thinks Soleno's shares should trade up at least 20% on Acadia Pharmaceuticals' failure in PWS, Prader-Willi syndrome. The firm remains bullish on VYKAT's launch and would be a buyer at these levels into Q3 print. Wells has an Overweight rating on Soleno with a price target of $123 on the shares.

Wells Fargo

Overweight

initiated

$123

2025-08-20

Reason

Wells Fargo

Price Target

$123

2025-08-20

initiated

Overweight

Reason

Wells Fargo initiated coverage of Soleno Therapeutics with an Overweight rating and $123 price target. The shares are down 23% this month on concerns over Vykat's satiety, competition and and its recent financing which could be a sign of no near-term takeover, the analyst tells investors in a research note. Wells views the concerns as overblown. Vykat's launch in Prader-Willi syndrome remains early, and the significant unmet should drive meaningful near-term uptake, the analyst tells investors in a research note. Wells recommends buying Soleno shares on the recent pullback.

H.C. Wainwright

Buy

maintain

$100 -> $110

2025-08-18

Reason

H.C. Wainwright

Price Target

$100 -> $110

2025-08-18

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Soleno Therapeutics to $110 from $100 and keeps a Buy rating on the shares. The firm says Citizen Petitions usually do not result in withdrawals of products from the U.S. market, as over 80% of those filed since 2001 have been denied or failed to elicit a response from the FDA. It updated the company's model post the Q2 report.

Oppenheimer

Outperform

maintain

$105 -> $110

2025-08-07

Reason

Oppenheimer

Price Target

$105 -> $110

2025-08-07

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Soleno Therapeutics to $110 from $105 and keeps an Outperform rating on the shares. The firm notes Vykat XR sales of $32.7M in its first launch quarter came in line with last month's pre-announcement. With a U.S. launch trending toward cash-flow positive and EU sales poised to begin next year, Oppenheimer views Soleno as a highly attractive, clean growth story.

Valuation Metrics

The current forward P/E ratio for Soleno Therapeutics Inc (SLNO.O) is 13.94, compared to its 5-year average forward P/E of -5.18. For a more detailed relative valuation and DCF analysis to assess Soleno Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.18

Current PE

13.94

Overvalued PE

13.12

Undervalued PE

-23.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

1.08

Current EV/EBITDA

8.59

Overvalued EV/EBITDA

5.56

Undervalued EV/EBITDA

-3.40

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

73.82

Current PS

6.24

Overvalued PS

303.84

Undervalued PS

-156.21

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 1314.42% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 1314.42% over the last month.

Sold

Bought

SLNO News & Events

Events Timeline

No data

News

7.0

01-09Globenewswire

Soleno Therapeutics Faces Investigation After Vykat XR Price Drop of 26.59%

7.0

01-08Globenewswire

Bragar Eagel & Squire Investigates Soleno, Avita, and Coty for Potential Securities Violations

7.0

01-06Globenewswire

Soleno Therapeutics Faces Investigation Over Vykat XR Safety Claims, Stock Plummets 26.59%

People Also Watch

Frequently Asked Questions

What is Soleno Therapeutics Inc (SLNO) stock price today?

The current price of SLNO is 43 USD — it has decreased -5.49 % in the last trading day.

What is Soleno Therapeutics Inc (SLNO)'s business?

Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.

What is the price predicton of SLNO Stock?

What is Soleno Therapeutics Inc (SLNO)'s revenue for the last quarter?

Soleno Therapeutics Inc revenue for the last quarter amounts to 66.02M USD, decreased % YoY.

What is Soleno Therapeutics Inc (SLNO)'s earnings per share (EPS) for the last quarter?

Soleno Therapeutics Inc. EPS for the last quarter amounts to 0.47 USD, decreased -125.68 % YoY.

What changes have occurred in the market's expectations for Soleno Therapeutics Inc (SLNO)'s fundamentals?

How many employees does Soleno Therapeutics Inc (SLNO). have?

Soleno Therapeutics Inc (SLNO) has 92 emplpoyees as of January 10 2026.

What is Soleno Therapeutics Inc (SLNO) market cap?

Today SLNO has the market capitalization of 2.31B USD.